Market Overview

Arrowhead Research Up Over 6% Following CNBC Comments


Shares of Arrowhead Research (NASDAQ: ARWR) are trending higher following bullish comments from CNBC’s Fast Money.

“Upside 100 to 200 percent- downside 20 percent,” said Robyn Karnauskas, Deutsche Bank biotechnology director.

Arrowhead is currently developing a drug to treat hepatitis B and is expected to release data on its progress in the third quarter.

Karnauskas also commented that Arrowhead is a likely takeout target. This is often the case for small pharmaceutical companies who are not partnered with a giant in the space to help with trials and commercialization.

Shares of Arrowhead are up nearly seven percent Wednesday to $12.15.

Latest Ratings for ARWR

Dec 2018Cantor FitzgeraldMaintainsOverweightOverweight
Sep 2018Chardan CapitalMaintainsBuyBuy
Sep 2018B. Riley FBRUpgradesNeutralBuy

View More Analyst Ratings for ARWR
View the Latest Analyst Ratings

Posted-In: CNBC CNBC Fast Money Robyn KarnauskasAnalyst Color Analyst Ratings Media


Related Articles (ARWR)

View Comments and Join the Discussion!

Latest Ratings

EXRRaymond JamesDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Wells Fargo Downgrades VMware On High Growth Estimates (VMW)

UPDATE: UBS Upgrades Seattle Genetics